je.st
news
Home
› Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER
Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER
2015-09-30 08:56:43| drugdiscoveryonline News Articles
Osmotica Pharmaceutical Corp. (privately held), a global specialty pharmaceutical corporation developing best-in-class therapeutics for the treatment of CNS diseases, announced recently that the New Drug Application (NDA) for OntinuaTM ER has been accepted for filing by the U.S. Food and Drug Administration (FDA)
Tags: the
for
er
program
Category:Biotechnology and Pharmaceuticals